Full Press Release Details
Adagene Presents Clinical Data from NEObodyTM
Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement
-ADG106, a fully human, ligand-blocking, agonistic
anti-CD137 antibody demonstrated a favorable safety profile
SAN FRANCISCO, Calif. and SUZHOU, China, May 19,
2021 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed
to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data from its ADG106 NEObodyTM
program. Results from Phase I, open-label, dose-escalation, single center (NCT03802955) and multicenter (NCT03707093) studies of
ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma were presented in an abstract
at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. In these Phase I trials, ADG106 monotherapy exhibited a favorable
safety profile and demonstrated promising clinical efficacy in biomarker positive patients. ADG106 is a fully human, ligand-blocking,
agonistic anti-CD137 IgG4 antibody (mAb) engineered using Adagene's proprietary NEObody platform technology.
"We are very pleased with the original finding
of a predictive biomarker for our anti-CD137 agonist and its association with tumor shrinkage," said Peter Luo, Ph.D., Co-founder,
Chief Executive Officer and Chairman of Adagene. "ADG106 has been well tolerated in dose escalation and extensive expansion cohorts
at dosage of up to 5 mg/kg, which exceeds that of other anti-CD137 agonists. Further, this clinical data demonstrates the power of our
proprietary NEObody platform designed to generate antibodies with novel mechanisms of action by targeting unique and highly conserved
epitopes. We believe these results, together with analyses of PK and PD data from around 100 patient population, support the recommended
dose regimen for ongoing clinical development of ADG106 as monotherapy and in combination with anti-PD-1 and other therapies. We look
forward to multiple upcoming studies as we continue to advance our ADG106 clinical program."
"Predictive biomarkers for patient stratification
are critical to advances in precision immuno-oncology. It's compelling to identify a predictive biomarker for anti-CD137 agonism
that shows a strong correlation between ADG106 treatment and tumor shrinkage," said Hua Gong, M.D. Ph.D., Chief Operating Officer
and Head of Precision Medicine of Adagene. "In an upcoming global Phase Ib/II trial (ADG106-2001), we plan to enrich for populations
expressing our predictive biomarker in order to demonstrate a clinical benefit to ADG106 therapy. Our predictive biomarker has the potential
to optimize favorable treatment options and enable oncologists to preselect cancer patients who are likely to benefit from ADG106 treatment.
In our continuing commitment to the development of precision immunotherapies,
Adagene has established a center of excellence for precision medicine
in San Diego with cutting-edge technologies to support biomarker-guided clinical trials."
Interim data for the ongoing Phase 1 clinical
ADG106-1001 and ADG106-1002 Phase I trials have
successfully completed enrollment of nearly 100 patients with advanced solid tumors and/or non-Hodgkin's lymphoma in the US and
China, respectively. Limited TEAEs, i.e., liver toxicity or hematologic abnormalities, were observed. Following a productive end-of-phase
I (EOP1) meeting about our ADG106 biomarker-stratified trial design with the FDA, Adagene made a new submission
(ADG106-2001) to stratify patients using the predictive biomarker prior to treatment with ADG106 as monotherapy and its combination with
anti-PD-1 therapy. In March 2021, Adagene initiated patient enrollment in China for ADG106-1008 (NCT04775680) a multicenter, open-label,
Phase Ib/II study of ADG106 in combination with PD-1 antibody in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. Preparations
are underway for the ADG106-1003 trial in Australia to evaluate ADG106 in combination with other therapies in advanced solid tumors and
hematological malignancies.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven,
clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered
by its proprietary DPL platform, composed of NEObodyTM, SAFEbodyTM, and POWERbodyTM technologies, Adagene's
highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global
partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com.
ADG106, is a fully human ligand-blocking, agonistic
anti-CD137 Immunoglobulin G4, or IgG4, mAb, being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma,
or NHL. CD137 stimulates the immune system to attack cancer cells and is a key driver for long-lasting T-cell proliferation and survival.
In preclinical studies, we observed that ADG106 had robust antitumor activity and was well tolerated as a single agent and in combination
with the existing standard-of-care and other immuno-oncology therapies. ADG106 activates CD137 in a native ligand-like fashion, blocks
reverse signaling of CD137 ligand, and has potent cross-linking via Fc receptor. Because of this novel mechanism of action, ADG106 was
observed to favorably balance CD137-induced toxicity and CD137 agonism, which we believe has potential to address the limitations of other
existing anti-CD137 therapies.
Safe Harbor Statement
This press release contains forward-looking statements,
including statements regarding data from the ADG106 Phase I clinical trial, the potential implications of clinical data for patients,
and Adagene's advancement of, and anticipated clinical development, regulatory milestones and commercialization of ADG106. Actual
results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including
but not limited to Adagene's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its
drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant
regulatory authorities regarding regulatory approval of Adagene's drug candidates; Adagene's ability to achieve commercial
success for its drug candidates, if approved; Adagene's ability to obtain and maintain protection of intellectual property for its
technology and drugs; Adagene's reliance on third parties to conduct drug development, manufacturing and other services; Adagene's
limited operating history and Adagene's ability to obtain additional funding for operations and to complete the development and
commercialization of its drug candidates; Adagene's ability to enter into additional collaboration agreements beyond its existing
strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene's clinical development, commercial
and other operations, as well as those risks more fully discussed in the "Risk Factors" section in Adagene's filings
with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene,
and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.